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AbstrAct
The goal of treatment of leptomeningeal metastasis is 
to improve survival and to maintain quality of life by 
delaying neurological deterioration. Tumour-specific 
therapeutic options include intrathecal pharmacotherapy, 
systemic pharmacotherapy and focal radiotherapy. 
Recently, improvement of leptomeningeal disease–related 
progression-free survival by adding intrathecal liposomal 
cytarabine to systemic treatment versus systemic 
treatment alone has been observed in a randomised 
phase III trial for patients with breast cancer with newly 
diagnosed leptomeningeal metastasis. Safety and efficacy 
of intrathecal administration of new agents such as 
trastuzumab are under evaluation. Systemic therapy 
using targeted agents and immunotherapy has also 
improved outcome in patients with brain metastasis, and 
its emerging role in the management of leptomeningeal 
metastasis needs to better studied in prospective series. 
Focal radiotherapy is commonly indicated for the treatment 
of macroscopic disease such as meningeal nodules or 
clinically symptomatic central nervous system structures, 
for example, base of skull with cranial nerve involvement 
or cauda equine syndrome. The role of whole brain 
radiotherapy is decreasing. An individualised combination 
of different therapeutic options should be used considering 
the presentation of leptomeningeal metastasis, as well as 
the histological and molecular tumour characteristics, the 
presence of concomitant brain and systemic metastases, 
and prior cancer-directed treatments.
IntroduCtIon
Leptomeningeal metastasis is defined as the 
spread of tumour cells within the leptome-
ninges and the subarachnoid space. Approx-
imately 10% of patients with solid cancer 
will present with leptomeningeal metastases 
during the course of disease, commonly in 
the context of progressive systemic disease. 
The incidence of central nervous system 
metastasis, including leptomeningeal metas-
tases, seems to be increasing, possibly due 
to improved survival of patients with cancer 
related to the development of new systemic 
agents that are probably less effective within 
the central nervous system compartment 
than outside, and to improved diagnostic 
assessment. Breast cancer, lung cancer and 
melanoma are the main primary tumours in 
patients with leptomeningeal metastasis.
The diagnosis of leptomeningeal metas-
tases can be challenging. It is based on 
clinical evaluation, cerebrospinal MRI and 
cerebrospinal fluid (CSF) analysis. According 
to EANO–ESMO guidelines, the diagnosis of 
leptomeningeal metastases can be confirmed 
by detection of tumour cells in the CSF, 
probable in presence of typical clinical and 
imaging signs in a patient with a known 
cancer, or possible (table 1).1 The classifica-
tion of leptomeningeal metastasis considers 
also the imaging presentation which guides 
clinical decision-making independently of 
the identification of tumour cells in the CSF. 
Four types have been defined: type A with 
linear leptomeningeal contrast enhancement 
only, type B with leptomeningeal nodules 
only, type C with the combination of both, 
and type D without positive CSF cytology and 
with a MRI that is normal except for poten-
tially hydrocephalus.
Goal of the treatment
Survival for patients with leptomeningeal 
metastases is poor, limited to a few months in 
most patients. The median survival has been 
estimated at 3.5 to 4.4 months for leptome-
ningeal metastases from breast cancer, 3 to 
6 months for leptomeningeal metastases 
from lung cancer and 1.7 to 2.5 months for 
leptomeningeal metastases from melanoma. 
Neurological symptoms and signs are usually 
fixed and rarely improve with therapeutic 
interventions. The goal of treatment is there-
fore to prolong survival and to maintain 
quality of the life by delaying further neuro-
logical deterioration.
Prognostic factors
Performance status at diagnosis of leptome-
ningeal metastasis diagnosis is the most impor-
tant prognostic factor. Other factors include 
the type of primary tumour, the protein level 
in the CSF at diagnosis, the administration 
of systemic or intrathecal pharmacotherapy, 
and initial response to treatment. The role of 
whole brain radiotherapy (WBRT) regarding 
overall survival remains controversial.
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Table 1 EANO–ESMO subtypes of leptomeningeal metastases, adapted from the EANO–ESMO leptomeningeal metastases 
guidelines (Le Rhun et al1)
Cytology/
biopsy MRI Confirmed Probable* Possible*
Lack of 
evidence
Type I: positive 
CSF cytology or 
biopsy
IA + Linear + n.a. n.a. n.a.
IB + Nodular + n.a. n.a. n.a.
IC + Linear+nodular + n.a. n.a. n.a.
ID + Normal + n.a. n.a. n.a.
Type II: clinical 
findings and 
neuroimaging only
IIA − or equivocal Linear n.a.† With typical 
clinical signs
Without 
typical clinical 
signs
n.a.
IIB − or equivocal Nodular n.a. With typical 
clinical signs
Without 
typical clinical 
signs
n.a.
IIC − or equivocal Linear+nodular n.a. With typical 
clinical signs
Without 
typical clinical 
signs
n.a.
IID − or equivocal Normal n.a. n.a. With typical 
clinical signs
Without 
typical clinical 
signs
*requires a history of cancer
†not applicable
CSF, cerebrospinal fluid.
therapeutic options for patients with leptomeningeal 
metastases
Therapeutic strategies include intrathecal pharmaco-
therapy, systemic pharmacotherapy and radiotherapy. 
Intrathecal therapy is widely used for the treatment of 
leptomeningeal metastases.2 There is a rationale to use 
intrathecal treatment in patients with floating tumour 
cells in the CSF and for linear diffuse or ependymal 
spread enhancement. However, intrathecal therapy has 
only a limited penetration into solid tumour lesions and 
may be inefficient and even toxic in case of CSF flow 
obstructions. In the latter situation, radiotherapy can be 
used to restore CSF flow—successful restoration should 
be checked prior the use of an intrathecal treatment.
Only six randomised trials on the treatment of leptome-
ningeal metastases have been reported.3–8 Four trials 
have compared different regimens of intra-CSF chemo-
therapy in patients with leptomeningeal metastases from 
various primary tumours. Two trials have explored the 
role of adding intra-CSF chemotherapy to systemic treat-
ment for the management of leptomeningeal metastases 
from breast cancer. In the first trial, the combination 
of intraventricular methotrexate and systemic chemo-
therapy failed to improve the survival in the combined 
treatment arm (7.57 months in the systemic therapy only 
arm vs 4.57 months in the combined modality arm).6 Yet, 
enrolment was stopped after 35 instead of 50 patients 
because of poor accrual, and a high rate of ventricular 
infection was noted with 18% of reservoir revisions which 
may have negatively influenced outcome in the experi-
mental arm. In the Depo-Sein trial (NCT01645839), 73 
patients were randomised between systemic treatment 
alone and liposomal cytarabine plus systemic treatment. 
The main objective was to demonstrate that adding 
intrathecal liposomal cytarabine to systemic treatment 
improved leptomeningeal metastases–related progres-
sion-free survival (PFS). Leptomeningeal metastases PFS 
was 3.8 months in the combined arm versus 2.2 in the 
systemic treatment alone arm (HR 0.61, 95% CI 0.38 to 
0.98, p=0.04) in the intent-to-treat population. Quality of 
life was preserved in the experimental arm. No significant 
difference was observed in terms of overall survival in the 
intent-to-treat population; however, the adjusted HR for 
overall survival was 0.60 (0.35–1.02) with p=0.06 in the 
intent-to-treat population.1
The three agents mainly used for intra-CSF treatment 
of leptomeningeal metastasis are methotrexate, (lipo-
somal) cytarabine and thiotepa. Other compounds are 
also under evaluation. Trastuzumab has been evaluated 
in a phase I study in patients with breast cancer with 
leptomeningeal metastases with Her2-positive tumours, 
with a good tolerance (NCT01373710).9 Data of a second 
trial on safety of dose-escalated intrathecal trastuzumab 
are still pending (NCT01325207).
Intrathecal pharmacotherapy can be administered via 
repeated lumbar punctures or via ventricular devices. The 
ventricular route has several advantages, such as avoiding 
delivery of the drug into the epidural or subdural space, 
allowing a uniform distribution of the drug and better 
patient comfort. The safety of ventricular devices has 
been confirmed in different cohorts with revision rates 
below 7.4%. A longer PFS was observed for methotrexate, 
but not for liposomal cytarabine, when using a ventric-
ular device in a secondary analysis of a randomised trial, 
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presumably due to the different half-lives of the agents.10 
Altogether, clinical experience and available evidence 
favour the intraventricular route.
Systemic pharmacotherapy, if active, should cover 
leptomeningeal lesions with contrast enhancement, 
reflecting absence of an intact blood–brain or spinal cord 
barrier, because such pharmacotherapy should reach 
sites of disease just as good as intravenously administered 
contrast agent. The disruption of the blood–CSF barrier 
indicated by elevated CSF protein in many patients with 
leptomeningeal metastasis suggests that the subarachnoid 
space may be reached by systemic pharmacotherapy to a 
certain extent, too. No randomised dedicated trials to 
explore the role of systemic pharmacotherapy in patients 
with leptomeningeal metastases have been conducted 
and only few data regarding systemic pharmacotherapy 
are available in this population. Systemic agents should 
be selected according to the primary tumour and its 
molecular characteristics and prior therapy. Among 32 
patients with heavily pre-treated leptomeningeal metas-
tasis with EGFR-mutant non-small cell lung cancer, 
including 11 patients with the Thr790Met mutation, 
treated by osimertinib, 10 had an objective imaging 
response.11 Partial responses and stable disease have 
been reported after high-dose intravenous thiotepa,12 
ANG1005, a paclitaxel/Angiopep-2 drug conjugate,13 
and a combination of bevacizumab with etoposide and 
cisplatin14 in patients with breast cancer with leptome-
ningeal metastases. A median survival of 16.9 weeks was 
noted in 25 patients with melanoma with leptomeningeal 
metastases, with a median of 21.7 weeks for 21 patients 
treated by immunotherapy or targeted therapy.15 A phase 
II trial met its primary endpoint with 44% patients alive at 
3 months in a cohort of 18 patients with leptomeningeal 
metastases from various primary tumours, including 15 
patients with breast cancer, treated with pembrolizumab 
(NCT02886585).
No trial has investigated the efficacy and safety of 
radiotherapy alone (WBRT or craniospinal irradiation) 
in patients with leptomeningeal metastases. Involved-
field radiotherapy using single fractions or fractionated 
regimens can be used to treat meningeal nodules and 
symptomatic cerebral or spinal sites. The safety of the 
combination of intrathecal methotrexate plus dexameth-
asone and concomitant involved field radiotherapy has 
been explored in a phase II trial in patients with leptome-
ningeal metastases from various primaries.16 A median 
overall survival of 6.5 months and 20.3% of grades 3–4 
adverse events were observed. Prolonged responses have 
been reported in patients presenting with nodular or bulky 
disease previously treated by WBRT. In the presence of 
cranial nerve impairment, irradiation of skull base, inter-
peduncular cistern or the two first cervical vertebrae may 
be indicated; irradiation of lumbosacral vertebrae may be 
indicated for cauda equina syndrome.1 No survival benefit 
of WBRT was observed in most retrospective studies of 
patients with leptomeningeal metastasis. WBRT may be 
an option in selected patients with extensive nodular 
diseased or symptomatic linear meningeal disease or in 
the presence of concomitant brain metastases. Cerebro-
spinal radiotherapy is rarely an option for adult patients 
with leptomeningeal metastases from solid cancers 
because of the risk of bone marrow toxicity, enteritis and 
mucositis in a context of concomitant systemic disease 
and the need of systemic pharmacotherapy.
Combination of treatment
The EANO–ESMO guideline provides expert opinion–
based recommendations for the diagnosis and the 
management of leptomeningeal metastases from solid 
tumours.1 Treatment depends on pathological and 
molecular tumour characteristics, prior treatments, 
general health status, concomitant brain metastases, the 
evolution of the extra-CNS disease and the presentation 
of leptomeningeal metastases (figure 1).
If tumour cells are found in the CSF, intrathecal phar-
macotherapy is commonly recommended, irrespective of 
the MRI presentation. A modification of systemic phar-
macotherapy should always be considered if leptomenin-
geal metastases are diagnosed. Focal radiotherapy should 
be given for symptomatic nodular disease or in presence 
of symptomatic lesions of cranial nerves or cauda equina.
If no tumour cells are detected in the CSF, intrathecal 
therapy can still be considered in the presence of linear 
meningeal contrast enhancement. It is not recommended 
in the presence of nodular meningeal disease only.
Supportive care
Supportive care is particularly important in patients with 
leptomeningeal metastases. The lowest dose of steroids 
should be used for the shortest time. Seizures should be 
managed with drugs that do not interact with systemic 
treatments. Primary seizure prophylaxis is not recom-
mended. Symptomatic hydrocephalus may be relieved by 
ventriculoperitoneal shunt or a ventricular device. Patient 
and caregiver need for psycho-oncological support should 
be explored.
Assessment of leptomeningeal metastasis during follow-up
The follow-up of patients with leptomeningeal metas-
tases should be performed regularly to guide the ther-
apeutic strategy and to adjust supportive care. Clinical 
and imaging evaluations are usually part of the evalua-
tion of leptomeningeal metastases. The role of repeat 
CSF cytology remains controversial. The clinical evalua-
tion may be challenging as symptoms and signs may vary 
depending on the pattern of leptomeningeal metastasis 
lesions. Symptoms and signs related to brain metastases, 
extra-CNS progression, neurotoxicity or associated disease 
can be associated and difficult to distinguish. Thus, clin-
ical deterioration is not necessarily related to leptomenin-
geal metastasis progression, and biological, neurophysio-
logical and imaging explorations may be needed in case 
of neurological deterioration. Cerebrospinal MRI should 
be performed every 2 months for the first 6 months and 
then every 3 months in case of stable disease, preferably 
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+
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+
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+
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Figure 1 EANO ESMO Therapeutic approach to LM. +, recommended; (+), optional; -, not recommended; BM, brain 
metastases; CSF, cerebrospinal fluid; ECD, extracranial disease; IT, intrathecal; LM, leptomeningeal metastases; RT, 
radiotherapy; WBRT, whole brain radiotherapy.
on the same scanner or on scanners with the same field 
strength.1 Standardised tools should ideally be used for 
the clinical and imaging evaluation, but no validated tools 
are currently available. The imaging scorecard proposed 
by the RANO leptomeningeal metastasis group has 
been shown not to be useful in clinical practice,17 but is 
currently undergoing a revision and re-evaluation.
ConCluSIon
The treatment of leptomeningeal metastases needs to 
be individualised. The primary tumour and its systemic 
treatment options as well as clinical, imaging and cyto-
logical presentation of leptomeningeal metastases guides 
the combination of intrathecal therapy, systemic phar-
macotherapy and focal radiotherapy. A modification 
of the systemic treatment should be considered taking 
into account the histological and molecular subtype 
of the cancer. Involved-field radiotherapy may have a 
role for the treatment of meningeal nodules and clini-
cally symptomatic central nervous system involvement. 
The different options should be discussed according to 
general and neurological health status, presence of other 
metastatic sites, including brain metastases, and previous 
treatment. Dedicated trials are needed to improve levels 
of evidence for all therapeutic measures for patients with 
leptomeningeal metastases.
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